Search Results for "Kadian"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Kadian. Results 1 to 7 of 7 total matches.
See also: morphine
A Morphine/Naltrexone Combination (Embeda) for Pain
The Medical Letter on Drugs and Therapeutics • Mar 22, 2010 (Issue 1334)
capsules containing only morphine (Kadian) were similar
in morphine pharmacokinetics and in efficacy ...
The FDA has approved an agonist/antagonist combination of morphine and naltrexone (Embeda – King)
for treatment of chronic moderate to severe pain requiring around-the-clock analgesia for an extended
period of time. The addition of naltrexone is intended to prevent abuse of morphine.
Extended-Release Hydrocodone (Zohydro ER) for Pain
The Medical Letter on Drugs and Therapeutics • Jun 09, 2014 (Issue 1444)
(Pfizer) 30, 45, 60, 75, 90, 120 mg ER caps 30 mg q24h 24 hrs 159.00
Kadian (Actavis) 10, 20, 30, 40, 50 ...
The FDA has approved an extended-release oral formulation
of the opioid agonist hydrocodone (Zohydro ER –
Zogenix) for management of pain severe enough to
require continuous, long-term therapy and for which
alternative treatment options are inadequate. Zohydro ER
is the first single-ingredient hydrocodone product to be
marketed in the US. Hydrocodone has been available for
years in combination with acetaminophen (Vicodin, and
others) or ibuprofen (Vicoprofen, and others).
Extended-Release Hydrocodone (Hysingla ER) for Pain
The Medical Letter on Drugs and Therapeutics • May 11, 2015 (Issue 1468)
ER tabs 333.504
Morphine –
Kadian (Actavis) 10, 20, 30, 40, 50, 60, 70, 80, 30 mg q24h 12-24 hrs ...
The FDA has approved a second extended-release (ER)
formulation of the oral opioid agonist hydrocodone
(Hysingla ER – Purdue) for management of pain severe
enough to require continuous long-term therapy and
for which alternative treatment options are inadequate.
Hysingla ER tablets have abuse-deterrent properties
to discourage their misuse.
In Brief: Palladone Withdrawn
The Medical Letter on Drugs and Therapeutics • Aug 01, 2005 (Issue 1214)
Oramorph opioids MS Contin Morphine Kadian Hydromorphone ...
The Medical Letter review of Palladone (hydromorphone HCl) extended-release capsules (March 14, 2005) warned that a lethal dose could be released if the new formulation was taken with alcohol. Because of that risk, the FDA asked the manufacturer (Purdue) to withdraw the drug from the market (FDA News. July 13, 2005; FDC Reports – “The Pink Sheet” July 18, 2005; 67:3).
Palladone for Chronic Pain
The Medical Letter on Drugs and Therapeutics • Mar 14, 2005 (Issue 1204)
Oramorph SR – Roxane 15-, 30-, 60-, 100-mg tabs 47.40
Kadian – Alpharma 20-, 30-, 50-, 60-, 100-mg caps 20 ...
A once-daily extended-release (ER) oral formulation of the opioid analgesic hydromorphone hydrochloride (Palladone - Purdue Pharma) has been approved by the FDA for treatment of opioid-tolerant patients with persistent moderate to severe pain. Hydromorphone HCl, a semisynthetic congener of morphine and active metabolite of hydrocodone that has been used since the 1920s, is also available in immediate-release oral, injectable and suppository forms (Dilaudid, and others).
Comparison Table: Some Oral/Transdermal Opioid Analgesics (online only)
The Medical Letter on Drugs and Therapeutics • Dec 12, 2022 (Issue 1665)
mg IR and 250 mg ER.
e202 Tridural Subsys OxyNeo OxyIR Apadaz M-Eslon Doloral Kadian Zytram Durela ...
View the Comparison Table: Some Oral/Transdermal Opioid Analgesics
Opioids for Pain
The Medical Letter on Drugs and Therapeutics • Dec 12, 2022 (Issue 1665)
Meperidine Durela Fentanyl Fentora Hydrocodone Hydromorph Contin Olinvyk Hysingla Kadian Lazanda lubiprostone ...
A new CDC guideline for prescribing opioids for pain
recently became available. Nonopioid drugs for pain
were reviewed in a previous issue.